CalciMedica Posts $21.3M Net Loss, Secures $15M Loan for R&D

TL;DR

CALC is burning cash with no revenue, but the new $15M loan buys them more time to prove their pipeline; it's a high-risk bet on future drug success.

AI Summary

CalciMedica, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company posted a net loss of $10.5 million for the three months ended June 30, 2025, and a net loss of $21.3 million for the six months ended June 30, 2025. Research and development expenses were $6.2 million for the three months and $12.5 million for the six months ended June 30, 2025, reflecting ongoing clinical trial activities. General and administrative expenses were $4.3 million for the three months and $8.8 million for the six months ended June 30, 2025. A significant business change was the entry into a Loan Agreement with Avenue Venture Opportunities Fund II, L.P. on February 28, 2025, providing a $15.0 million term loan facility. The company also completed a private placement in January 2024, raising gross proceeds of approximately $10.0 million through the sale of common stock and warrants. Key risks include the company's accumulated deficit of $305.8 million as of June 30, 2025, and its reliance on external financing to fund operations and clinical development. The strategic outlook remains focused on advancing its clinical pipeline, particularly with the proceeds from the recent financing activities.

Why It Matters

CalciMedica's continued net losses and reliance on external financing highlight the inherent risks in early-stage biotech. For investors, the $15.0 million loan from Avenue Venture Opportunities Fund II, L.P. provides a crucial, albeit temporary, lifeline for ongoing R&D, but dilution risk remains high given the company's need for future capital. Employees face job security tied to successful clinical development and funding, while customers (future patients) depend on the company's ability to bring its pipeline to market. In a competitive landscape, CalciMedica's ability to advance its drug candidates will determine its long-term viability against larger pharmaceutical players.

Risk Assessment

Risk Level: high — CalciMedica reported an accumulated deficit of $305.8 million as of June 30, 2025, and a net loss of $21.3 million for the six months ended June 30, 2025, indicating significant cash burn without revenue. The company's reliance on a $15.0 million term loan facility from Avenue Venture Opportunities Fund II, L.P. and prior private placements underscores its dependence on external financing, posing substantial going concern risks.

Analyst Insight

Investors should approach CALC with extreme caution, recognizing it as a highly speculative investment. Monitor the progress of their clinical trials and future financing activities closely, as continued losses and the need for additional capital could lead to further dilution or financial distress.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$21.3M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for the three and six months ended June 30, 2025, indicating pre-commercial stage.)
• -$21.3M — Net Loss (Net loss for the six months ended June 30, 2025, highlighting significant cash burn.)
• $12.5M — R&D Expense (Research and development expenses for the six months ended June 30, 2025, reflecting ongoing clinical trial costs.)
• $8.8M — G&A Expense (General and administrative expenses for the six months ended June 30, 2025.)
• $15.0M — Term Loan Facility (New financing secured from Avenue Venture Opportunities Fund II, L.P. on February 28, 2025.)
• $305.8M — Accumulated Deficit (Total accumulated deficit as of June 30, 2025, indicating historical losses.)

Key Players & Entities

• CalciMedica, Inc. (company) — filer of the 10-Q
• Avenue Venture Opportunities Fund II, L.P. (company) — lender in the $15.0 million loan agreement
• $10.5 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $21.3 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $6.2 million (dollar_amount) — research and development expenses for the three months ended June 30, 2025
• $12.5 million (dollar_amount) — research and development expenses for the six months ended June 30, 2025
• $4.3 million (dollar_amount) — general and administrative expenses for the three months ended June 30, 2025
• $8.8 million (dollar_amount) — general and administrative expenses for the six months ended June 30, 2025
• $15.0 million (dollar_amount) — term loan facility secured on February 28, 2025
• $305.8 million (dollar_amount) — accumulated deficit as of June 30, 2025

FAQ

Risk Factors

• Substantial Accumulated Deficit [high — financial]: As of June 30, 2025, CalciMedica has an accumulated deficit of $305.8 million. This indicates a history of significant net losses and raises concerns about the company's long-term financial viability without continued access to external funding.
• Reliance on External Financing [high — financial]: The company's operations and clinical development are heavily dependent on external financing. The recent $15.0 million term loan facility and prior private placement highlight this reliance. Any disruption in securing future funding could severely impact its ability to continue operations.
• Clinical Trial and Development Risks [high — operational]: CalciMedica is in the pre-commercial stage, with significant R&D expenses of $12.5 million for the six months ended June 30, 2025, dedicated to clinical trials. The success of these trials is critical for future revenue generation, and any setbacks or failures pose a substantial risk.
• Negative Operating Cash Flow [medium — financial]: The company reported a net loss of $21.3 million for the six months ended June 30, 2025, and no revenue. This implies a substantial negative operating cash flow, necessitating continuous funding to cover operational expenses.

Industry Context

CalciMedica operates in the highly competitive pharmaceutical industry, specifically focusing on developing treatments for critical care conditions. The industry is characterized by long development cycles, significant capital requirements, and stringent regulatory oversight. Success hinges on innovative drug discovery, successful clinical trials, and effective market penetration.

Regulatory Implications

As a biotechnology company in clinical development, CalciMedica is subject to rigorous oversight by regulatory bodies like the FDA. The success of its drug candidates depends on meeting strict clinical trial protocols and obtaining regulatory approval, which are complex and time-consuming processes.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates.
2. Assess future financing needs and sources.
3. Evaluate the competitive landscape for its therapeutic areas.

Key Dates

• 2025-06-30: End of Reporting Period — Marks the end of the period for which financial results are reported in the 10-Q.
• 2025-02-28: Loan Agreement with Avenue Venture Opportunities Fund II, L.P. — Secured a $15.0 million term loan facility, providing crucial capital for operations and development.
• 2025-01-01: Start of Six-Month Period — Beginning of the period for which R&D and G&A expenses are reported.
• 2024-01-19: Completion of Private Placement — Raised approximately $10.0 million in gross proceeds, bolstering the company's cash reserves.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability and its reliance on external funding to sustain operations.)

Pre-commercial Stage

A phase in a company's lifecycle where it has not yet begun generating revenue from product sales, typically focusing on research, development, and clinical trials. (Explains the absence of revenue for CalciMedica and highlights the focus on pipeline development.)

Term Loan Facility

A type of loan from a bank or other financial institution that has a specified repayment schedule and interest rate, often used for specific business purposes. (Represents a significant source of debt financing for CalciMedica, impacting its capital structure and future obligations.)

Private Placement

The sale of securities (like stock or warrants) to a select group of investors, rather than through a public offering. (Details a past financing event that provided capital to the company.)

Research and Development (R&D) Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Represents a major expenditure for CalciMedica, reflecting its investment in advancing its drug pipeline.)

Year-Over-Year Comparison

The current 10-Q filing for the period ending June 30, 2025, shows no revenue, consistent with the company's pre-commercial status, similar to prior periods. The net loss for the six months ($21.3 million) and R&D expenses ($12.5 million) reflect ongoing clinical development. A key development since the last filing is the securing of a $15.0 million term loan facility, indicating continued reliance on debt financing to fund operations and development.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CALC The Nasdaq Capital M

Filing Documents

• ck0001534133-20250630.htm (10-Q) — 3121KB
• ck0001534133-ex10_2.htm (EX-10.2) — 26KB
• ck0001534133-ex31_1.htm (EX-31.1) — 16KB
• ck0001534133-ex31_2.htm (EX-31.2) — 16KB
• ck0001534133-ex32_1.htm (EX-32.1) — 10KB
• ck0001534133-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-25-107334.txt ( ) — 11119KB
• ck0001534133-20250630.xsd (EX-101.SCH) — 1271KB
• ck0001534133-20250630_htm.xml (XML) — 2231KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 80 Item 3. Defaults Upon Senior Securities 80 Item 4. Mine Safety Disclosures 80 Item 5. Other Information 80 Item 6. Exhibits 81

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CALCIMEDICA, INC. Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 5,918 $ 7,935 Short-term investments 12,039 10,734 Prepaid clinical trial expenses 352 748 Other prepaid expenses and current assets 655 248 Total current assets 18,964 19,665 Property and equipment, net 105 119 Other assets 11 10 Total assets $ 19,080 $ 19,794 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,912 $ 1,998 Accrued clinical trial costs 670 820 Accrued expenses 895 866 Total current liabilities 3,477 3,684 Long-term liabilities Promissory note 8,500 — Warrant liability 1,000 1,700 Total liabilities 12,977 5,384 Commitments and contingencies (Note 8) Stockholders' equity Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 13,971,990 and 13,481,917 , issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 4 Additional paid-in capital 176,865 174,166 Accumulated deficit ( 170,762 ) ( 159,764 ) Accumulated other comprehensive (loss) income ( 4 ) 4 Total stockholders' equity 6,103 14,410 Total liabilities and stockholders' equity $ 19,080 $ 19,794 See accompanying notes to unaudited condensed consolidated financial statements. 2 CALCIMEDICA, INC. Condensed Consolidated Statemen ts of Operations (in thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025

View Full Filing

View this 10-Q filing on SEC EDGAR